On June 4, Abbott rose 3.02% in regular trading, trading at $91.09/share, with trading volume of $373 million. The stock was buoyed by two significant partnership announcements that reinforced Abbott's dominance in the continuous glucose monitoring (CGM) ecosystem.
On the news front, MiniMed announced an expanded collaboration with Abbott to commercialize a dual glucose-ketone sensor designed for integration with its automated insulin dosing systems. The new sensor, comparable in size to the existing Instinct sensor, enables real-time monitoring of both glucose and ketone levels, facilitating earlier detection of rising ketones and helping reduce the risk of diabetic ketoacidosis. The technology will integrate exclusively with MiniMed's smart dosing platforms. The dual sensor has not yet received US regulatory approval, with updates expected in coming months.
Simultaneously, Insulet announced that its Omnipod 5 automated insulin delivery system is now compatible with Abbott's FreeStyle Libre 3 Plus sensor in the US, further expanding user choice. The concurrent advancement of both partnerships solidifies Abbott's strategic position as a key CGM platform provider across multiple insulin delivery ecosystems.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments